诺华达成一项57亿美元许可交易

Core Insights - Novartis signed a licensing agreement with Monte Rosa worth up to $5.7 billion for the development of drugs targeting immune-mediated diseases [1] - Monte Rosa will receive an upfront payment of $120 million as part of the agreement [1] - Following the announcement, Monte Rosa's stock surged by 50% in pre-market trading [1]